Dr. Norman D. LaFrance FACNP, FACP, M.D. Net Worth

Dr. Norman D. LaFrance FACNP, FACP, M.D. biography

Dr. Norman D. LaFrance FACNP, FACP, M.D. is the Chief Medical Officer & Sr. VP at Plus Therapeutics.

How old is Dr D?

Dr D is 73, he's been the Chief Medical Officer & Sr. VP of Plus Therapeutics since . There are no older and 13 younger executives at Plus Therapeutics.

What's Dr D's mailing address?

Norman's mailing address filed with the SEC is C/O PLUS THERAPEUTICS INC., 4200 MARATHON BOULEVARD, SUITE 200, AUSTIN, TX, 78756.

Insiders trading at Plus Therapeutics

Over the last 5 years, insiders at Plus Therapeutics have traded over $4,518 worth of Plus Therapeutics stock and bought 251,584 units worth $410,360 . The most active insiders traders include Greg Petersen, Marc H Hedrick a Richard J Hawkins. On average, Plus Therapeutics executives and independent directors trade stock every 37 days with the average trade being worth of $8,201. The most recent stock trade was executed by Marc H Hedrick on 10 September 2024, trading 8,000 units of PSTV stock currently worth $9,840.

What does Plus Therapeutics do?

Plus Therapeutics, Inc., a clinical-stage pharmaceutical company, focuses on the development, manufacture, and commercialization of treatments for patients with cancer and other diseases. Its lead drug candidate is Rhenium-186 NanoLiposome, a patented radiotherapy that targets central nervous system cancers, including recurrent glioblastoma, leptomeningeal metastases, and pediatric brain cancers. It has a license agreement with NanoTx, Corp. to develop and commercialize NanoTx's glioblastoma treatment. The company was formerly known as Cytori Therapeutics, Inc. and changed its name to Plus Therapeutics, Inc. in July 2019. Plus Therapeutics, Inc. was founded in 1996 and is headquartered in Austin, Texas.

Plus Therapeutics executives and stock owners

Plus Therapeutics executives and other stock owners filed with the SEC include:

• Marc Hedrick,
  Chief Executive Officer, Director
• Dr. Marc H. Hedrick M.D.,
  Pres, CEO & Director
• Steven Kesten,
  President and Chief Medical Officer
• Seijiro Shirahama,
  President , Asia Pacific
• Annigje van Es-Johansson,
  Independent Director
• Greg Petersen,
  Independent Director
• Robert Lenk,
  Independent Director
• Howard Clowes,
  Independent Director
• Mark Marino,
  Chief Medical Officer
• Jeremy Hayden,
  Vice President - Business Development, General Counsel
• Desiree Smith,
  Principal Accounting Officer, Corporate Controller
• Gregory Stein,
  Senior Vice President of Clinical Development
• Andrew Sims,
  Chief Financial Officer, Vice President - Finance
• Richard Hawkins,
  Chairman of the Board
• Dr. Norman D. LaFrance FACNP, FACP, M.D.,
  Chief Medical Officer & Sr. VP
• Desiree Smith,
  Corp. Controller, Principal Financial & Accounting Officer
• Gary S. Titus CPA,
  Advisor
• Russ Havranek M.B.A., M.S.,
  VP of Corp. Strategy, New Product Planning & Investor Relations
• Dr. John K. Fraser,
  Chief Scientist
• Andrew J. Sims,
  VP of Fin. & CFO
• Es Johansson An Van,
  
• Norman D. La France,
  Chief Medical Officer